Carotenoid/Retinoid Modulation of Cellular Redox/Cancer
类胡萝卜素/类视黄醇对细胞氧化还原/癌症的调节
基本信息
- 批准号:6432261
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:antioxidants apoptosis benzopyrenes biological signal transduction carotenoids chemical carcinogenesis cysteine dietary supplements disease /disorder model gene expression genetically modified animals laboratory mouse lymphoma microarray technology molecular oncology neoplasm /cancer genetics neoplastic process nutrition aspect of cancer nutrition related tag oxidation reduction reaction retinoids
项目摘要
Results from recent prevention and intervention trials imply that consumption of antioxidant-rich foods early in disease states provides a protective advantage, while late intervention with dietary carotenoids/retinoids may exacerbates cancer. We are conducting a series of mechanism-based hypothesis driven studies designed to explain the paradoxical results observed in human intervention trials. We hypothesize that increased antioxidant cellular environment (provided by high levels of dietary supplementation with the chemical antioxidant N-acetyl-L-cysteine (NAC), or carotenoids/retinoids, will alter the cellular redox state and promote cancer in carcinogen initiated mice. The following specific aims are being carried out:1) Determination of the association between high levels of dietary supplementation with the antioxidant N-acetyl-L-cysteine (NAC) and the alteration of tumor progression of benzo[a]pyrene by quantitatively assessing cancer latency and incidence using genetically-altered mouse models of cancer.2)Determination of the mechanism an/or mode of action of the antioxidant N-acetyl-L-cysteine (NAC) altered cellular redox state on tumor progression via dysregulation of cell proliferation and apoptosis by investigation of altered patterns of gene expression in critical signal transduction pathways in situ.* Determination of the mechanism an/or mode of action of the antioxidant N-acetyl-L-cysteine (NAC) altered cellular redox state in vitro in splenocytes via dysregulation of cell proliferation and apoptosis by investigation of altered patterns of proliferation, apoptosis, and gene expression in critical signal transduction pathways. Thus far, we have observed that dietary NAC increases survival and reduces multiplicity of skin malignancies but increases the fraction of malignancies induced by topically administered B[a]P. The majority of the malignancies (keratoacanthomas, squamous carcinomas, and spindle cell tumors) induced in FVB/N-p53 deficient Tg.AC mice demonstrated mutant transgene ras expression and were nucleus positive for p53 (variable intensity from 0 to +4 areas) and treatment independent. Malignancies, both negative and positive for transgene expression were also negative for mutations in codon 12 and codon 61 of endogenous c-Ha-ras protooncogene. NAC alone is mitogenic to splenocytes. Currently, we are conducting an in life study (gamma irradiated FVB/N-heterozygous p53+/- mice at 0, 2, 4, or 6 Gy) with and without NAC supplementation in the diet. We have observed a decreased latency for thymic lymphoma and an increased incidence of thymic lymphoma after 24 wks (0/15 vs 10/15) in the controls versus 4 Gy plus NAC. These results may be explained, at least in part, by in vitro studies that show that lipopolysaccharide (LPS, a B-lymphocyte mitogen) induced splenic cell proliferation (3:1 T- to B-cell ratio) is significantly increased by NAC, but apoptosis was significantly suppressedSuppression of apoptosis was confirmed by independent assays (TUNEL and Annexin V). B-lymphocyte specificity was confirmed by flow cytometry using B- and T-lymphocyte specific monoclonal antibodies. When current post- and in-life studies are completed for histopathology, we will focus on investigation of the molecular mechanisms involved in antioxidant exacerbation of lymphomagenesis. These studies will include changes in gene expression at the mRNA and protein level as well as molecular genetic changes in signaling pathways critical to proliferation and apoptosis. In addition, in vitro studies will be focused on 1) mechanism of NAC associated suppression of apoptosis using microarray based gene expression, followed by confirmation using protein 2D gel electrophoresis and western analysis (where required for confirming dysregulated pathways).
最近的预防和干预试验的结果表明,在疾病状态早期食用富含抗氧化剂的食物提供了保护优势,而膳食类胡萝卜素/类维生素A的后期干预可能会加剧癌症。我们正在进行一系列基于机制的假设驱动的研究,旨在解释在人类干预试验中观察到的矛盾结果。我们假设,增加抗氧化剂细胞环境(由高水平的化学抗氧化剂N-乙酰-L-半胱氨酸(NAC)或类胡萝卜素/类维生素A的膳食补充剂提供)将改变细胞氧化还原状态,并促进致癌物引发的小鼠的癌症。 正在进行以下具体目标:1)通过使用基因改变的癌症小鼠模型定量评估癌症潜伏期和发病率,确定高水平膳食补充抗氧化剂N-乙酰-L-半胱氨酸(NAC)与苯并[a]芘改变肿瘤进展之间的关联。2)通过原位研究关键信号转导途径中基因表达模式的改变,确定抗氧化剂N-乙酰-L-半胱氨酸(NAC)通过细胞增殖和凋亡的失调改变细胞氧化还原状态对肿瘤进展的作用机制和/或模式。确定抗氧化剂N-乙酰-L-半胱氨酸(NAC)的作用机制和/或模式,通过研究关键信号转导途径中增殖、凋亡和基因表达的改变模式,通过细胞增殖和凋亡的失调在体外改变脾细胞的细胞氧化还原状态。到目前为止,我们已经观察到饮食NAC增加了存活率并减少了皮肤恶性肿瘤的多样性,但增加了由局部施用的B[a] P诱导的恶性肿瘤的分数。(角化棘皮瘤,鳞状细胞癌,在FVB/N-p53缺陷的Tg.AC小鼠中诱导的梭形细胞瘤)表现出突变的转基因ras表达,并且对p53呈核阳性(强度从0到+4区域变化)和治疗无关。 转基因表达阴性和阳性的恶性肿瘤,内源性c-Ha-ras原癌基因的密码子12和密码子61突变也是阴性的。 NAC单独对脾细胞具有促有丝分裂作用。 目前,我们正在进行一项在饮食中添加和不添加NAC的活体研究(0、2、4或6戈伊γ辐照FVB/N杂合p53+/-小鼠)。 我们观察到,与4戈伊加NAC相比,对照组胸腺淋巴瘤潜伏期缩短,24周后胸腺淋巴瘤发病率增加(0/15 vs 10/15)。 这些结果可以解释,至少部分地,在体外研究表明,脂多糖(LPS,B淋巴细胞有丝分裂原)诱导的脾细胞增殖(3:1 T-B-细胞比)显着增加NAC,但细胞凋亡显着抑制细胞凋亡的抑制证实了独立的测定(TUNEL和Annexin V)。 使用B-和T-淋巴细胞特异性单克隆抗体通过流式细胞术确认B-淋巴细胞特异性。 当目前的后期和活体研究完成组织病理学,我们将重点调查参与抗氧化剂加重淋巴瘤的分子机制。 这些研究将包括mRNA和蛋白质水平上基因表达的变化,以及对增殖和细胞凋亡至关重要的信号通路中的分子遗传变化。 此外,体外研究将集中在1)NAC相关的细胞凋亡抑制机制,使用基于基因表达的微阵列,然后使用蛋白质2D凝胶电泳和蛋白质印迹分析(需要确认失调途径)进行确认。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN EDGAR FRENCH其他文献
JOHN EDGAR FRENCH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN EDGAR FRENCH', 18)}}的其他基金
Mechanism(s) of Leukemogenesis in Genetically-Altered Mouse Models
基因改造小鼠模型中白血病发生的机制
- 批准号:
6432229 - 财政年份:
- 资助金额:
-- - 项目类别:
Carcinogen inactivation of tumor suppressor genes in p53 haploinsufficient mice.
p53 单倍体不足小鼠中肿瘤抑制基因的致癌灭活。
- 批准号:
6432252 - 财政年份:
- 资助金额:
-- - 项目类别:
CARCINOGEN INACTIVATION OF TUMOR SUPPRESSOR GENES IN P53 HAPLOINSUFFICIENT MICE.
P53 单倍体不足小鼠中肿瘤抑制基因的致癌灭活。
- 批准号:
6289910 - 财政年份:
- 资助金额:
-- - 项目类别:
Mechanism(s) Of Leukemogenesis In Genetically-altered Mo
基因改变的 Mo 中白血病发生的机制
- 批准号:
6837354 - 财政年份:
- 资助金额:
-- - 项目类别:
Genetic Susceptibility to Loss of Tumor Suppressor Gene Function
肿瘤抑制基因功能丧失的遗传易感性
- 批准号:
7967960 - 财政年份:
- 资助金额:
-- - 项目类别:
CAROTENOID/RETINOID MODULATION OF CELLULAR REDOX STATUS AND CANCER
类胡萝卜素/类维生素A调节细胞氧化还原状态和癌症
- 批准号:
6293840 - 财政年份:
- 资助金额:
-- - 项目类别:
Carcinogen Inactivation Of Tumor Suppressor Genes In P53
P53 中肿瘤抑制基因的致癌物质失活
- 批准号:
6542232 - 财政年份:
- 资助金额:
-- - 项目类别:
Carcinogen Inactivation Of Tumor Suppressor Genes In P53
P53 中肿瘤抑制基因的致癌物质失活
- 批准号:
6681846 - 财政年份:
- 资助金额:
-- - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual